How to buy Acceleron Pharma stock | 115.63

Acceleron Pharma Inc is a biotechnology business based in the US. Acceleron Pharma shares (XLRN) are listed on the NASDAQ and all prices are listed in US Dollars. Acceleron Pharma employs 237 staff and has a trailing 12-month revenue of around USD$106 million.

How to buy shares in Acceleron Pharma

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Acceleron Pharma. Find the stock by name or ticker symbol: XLRN. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Acceleron Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$115.63, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Acceleron Pharma, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Acceleron Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Acceleron Pharma share price

Use our graph to track the performance of XLRN stocks over time.

Acceleron Pharma shares at a glance

• Key figures

Information last updated 2020-11-24.

Latest market close	USD$115.63
52-week range	USD$46 - USD$124.01
50-day moving average	USD$112.3297
200-day moving average	USD$102.7522
Wall St. target price	USD$131.77
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.44

Buy Acceleron Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Acceleron Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Acceleron Pharma Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Acceleron Pharma price performance over time

Historical closes compared with the close of $115.63 from 2020-11-16

1 week (2020-11-19)	N/A
1 month (2020-10-30)	10.57%
3 months (2020-08-26)	N/A
6 months (2020-05-26)	N/A

1 year (2019-11-26)	N/A
2 years (2018-11-26)	N/A
3 years (2017-11-26)	N/A
5 years (2015-11-26)	N/A

Acceleron Pharma financials

Revenue TTM	USD$106 million
Gross profit TTM	USD$-79,960,000
Return on assets TTM	-11.53%
Return on equity TTM	-19.44%
Profit margin	-124.73%
Book value	$14.906
Market capitalisation	USD$6.8 billion

TTM: trailing 12 months

Shorting Acceleron Pharma shares

There are currently 3.6 million Acceleron Pharma shares held short by investors – that's known as Acceleron Pharma's "short interest". This figure is 8.3% down from 3.9 million last month.

There are a few different ways that this level of interest in shorting Acceleron Pharma shares can be evaluated.

Acceleron Pharma's "short interest ratio" (SIR)

Acceleron Pharma's "short interest ratio" (SIR) is the quantity of Acceleron Pharma shares currently shorted divided by the average quantity of Acceleron Pharma shares traded daily (recently around 285704.68253968). Acceleron Pharma's SIR currently stands at 12.6. In other words for every 100,000 Acceleron Pharma shares traded daily on the market, roughly 12600 shares are currently held short.

However Acceleron Pharma's short interest can also be evaluated against the total number of Acceleron Pharma shares, or, against the total number of tradable Acceleron Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acceleron Pharma's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Acceleron Pharma shares in existence, roughly 60 shares are currently held short) or 0.0798% of the tradable shares (for every 100,000 tradable Acceleron Pharma shares, roughly 80 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Acceleron Pharma.

Find out more about how you can short Acceleron Pharma stock.

Acceleron Pharma share dividends

We're not expecting Acceleron Pharma to pay a dividend over the next 12 months.

Acceleron Pharma share price volatility

Over the last 12 months, Acceleron Pharma's shares have ranged in value from as little as $46 up to $124.01. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acceleron Pharma's is 0.5231. This would suggest that Acceleron Pharma's shares are less volatile than average (for this exchange).

Acceleron Pharma overview

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of Acceleron Pharma is owned by insiders or institutions?

  Currently 12.093% of Acceleron Pharma shares are held by insiders and 90.278% by institutions.

• How many people work for Acceleron Pharma?

  Latest data suggests 237 work at Acceleron Pharma.

• When does the fiscal year end for Acceleron Pharma?

  Acceleron Pharma's fiscal year ends in December.

• Where is Acceleron Pharma based?

  Acceleron Pharma's address is: 128 Sidney Street, Cambridge, MA, United States, 02139

• What is Acceleron Pharma's ISIN number?

  Acceleron Pharma's international securities identification number is: US00434H1086

• What is Acceleron Pharma's CUSIP number?

  Acceleron Pharma's Committee on Uniform Securities Identification Procedures number is: 00434H108